The utility of syndecan-1 circulating levels as a biomarker in patients with previous or active COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases

Research

Douglas D. Fraser¹  Mitra Norouzi²  Sanam Alilou³  Amir Hossein Behnoush⁴  Amirmohammad Khalaji⁴  Elina Ghondaghsaz⁵ 

[1] Children’s Health Research Institute, London, ON, Canada;Lawson Health Research Institute, London, ON, Canada;Department of Pediatrics, Western University, London, ON, Canada;Department of Physiology & Pharmacology, Western University, London, ON, Canada;Department of Clinical Neurological Sciences, Western University, London, ON, Canada;Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran;School of Medicine, Iran University of Medical Sciences, Tehran, Iran;School of Medicine, Tehran University of Medical Sciences, Poursina St., Keshavarz Blvd, 1417613151, Tehran, Iran;Undergraduate Program in Neuroscience, University of British Columbia, Vancouver, BC, Canada;

关键词: Syndecan-1;    COVID-19;    Diagnosis;    Prognosis;    Glycocalyx;    Systematic review;    Meta-analysis;   

DOI  :  10.1186/s12879-023-08473-9

 received in 2023-05-10, accepted in 2023-07-20,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundWith the emergence of coronavirus disease of 2019 (COVID-19), several blood biomarkers have been identified, including the endothelial biomarker syndecan-1, a surface proteoglycan. In the current systematic review and meta-analysis, we aimed to assess the diagnostic and prognostic role of syndecan-1 in COVID-19.MethodsPubMed, Embase, Scopus, and Web of Science, as international databases, were searched for relevant studies measuring blood syndecan-1 levels in COVID-19 patients, COVID-19 convalescents, and healthy control subjects, in patients with different COVID-19 severities and/or in COVID-19 patients with poor outcomes. Random-effect meta-analysis was performed using STATA to calculate the standardized mean difference (SMD) and 95% confidence interval (CI) for the comparison between COVID-19 patients and healthy control subjects or COVID-19 convalescents and controls.ResultsAfter screening by title/abstract and full text, 17 studies were included in the final review. Meta-analysis of syndecan-1 levels in COVID-19 compared with healthy control subjects revealed that patients with COVID-19 had significantly higher syndecan-1 levels (SMD 1.53, 95% CI 0.66 to 2.41, P < 0.01). In contrast, COVID-19 convalescent patients did not show significant difference with non-convalescents (SMD 0.08, 95% CI -0.63 to 0.78, P = 0.83). Regarding disease severity, two studies reported that more severe forms of the disease were associated with increased syndecan-1 levels. Moreover, patients who died from COVID-19 had higher syndecan-1 levels compared with survivors (SMD 1.22, 95% CI 0.10 to 2.33, P = 0.03).ConclusionCirculating syndecan-1 level can be used as a biomarker of endothelial dysfunction in COVID-19, as it was increased in COVID-19 patients and was higher in more severe instances of the disease. Further larger studies are needed to confirm these findings and further enlighten the role of syndecan-1 in clinical settings.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 2

12888_2023_5012_Article_IEq5.gif

12888_2023_5012_Article_IEq4.gif

12888_2023_5012_Article_IEq2.gif